Metagenomi Inc

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit­ing toolbox, ther­a­peu­tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Metagenomi Inc For Securities Fraud And Individuals With Losses Are Urged To Join

Twelve-month durability data from Metagenomi's ongoing nonhuman primate (NHP) study  in hemophilia A remains generally consistent with data previously released at 4.5 months

Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc. May Have Violated Securities Regulations And The Schall Law Firm Seeks Investors' Participation In An Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Metagenomi Inc For Potential Securities Fraud And Stockholders Can Lend A Hand

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors With Losses In Metagenomi Inc. Are Invited To Partake In An Inquiry With The Schall Law Firm Into Whether Securities Laws Were Violated

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc Is Being Looked Into For Securities Fraud And The Schall Law Firm Encourages Shareholder Participation

NEW YORK, NY / ACCESSWIRE / August 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

Investors who Lost Money on Metagenomi, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - MGX

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Can Join The Schall Law Firm In An Inquiry Into Whether Metagenomi Inc. Committed Securities Law Infractions

AI-generated, compact SMART nucleases demonstrated robust genome editing activity in vitro in mammalian cells at multiple therapeutically relevant loci

Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc Is Being Looked Into For Securities Fraud And Shareholders Are Urged To Participate With The Schall Law Firm

EMERYVILLE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that it will present during the following upcoming investor conferences:

Metagenomi to Participate in Upcoming Investor Conferences

LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Metagenomi Inc. For Possible Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc. Is Being Looked Into For Securities Fraud And The Schall Law Firm Wants Shareholders To Offer Assistance

NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

Metagenomi, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – MGX

Metagenomi Being Investigated on Behalf of Metagenomi, Inc. Investors; Contact Levi & Korsinsky For Details

LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Investors To Join An Investigation Into Metagenomi Inc For Possible Securities Law Violations

NEW YORK, NY / ACCESSWIRE / August 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

Levi & Korsinsky Reminds Shareholders of an Investigation into Metagenomi, Inc. (MGX) Regarding Potential Securities Fraud Allegations

LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc Is Being Inquired Into For Securities Fraud And The Schall Law Firm Seeks Shareholder Participation

NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

Metagenomi, Inc. (MGX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

An Investigation Into Metagenomi Inc For Securities Violations Has Been Opened By The Schall Law Firm And Stockholders Are Encouraged To Take Part

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc Is Being Inquired Into By The Schall Law Firm For Possible Securities Fraud And Investors With Losses Are Invited To Join

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

An Inquiry Into Metagenomi Inc Has Been Opened By The Schall Law Firm For Possible Securities Fraud And Shareholders Are Encouraged To Participate

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

ATTENTION MGX SHAREHOLDERS: Investors Who Lost Money on Metagenomi, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc Is Being Investigated By The Schall Law Firm For Potential Securities Laws Violations And Urges Investors To Join

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

News for Metagenomi Inc Stock (MGX)